Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tyrosine kinase inhibitors

a technology of tyrosine kinase and inhibitor, which is applied in the direction of biocide, drug composition, antibody medical ingredients, etc., can solve the problems of visual degeneration, tumor growth is susceptible to antiangiogenic effects,

Inactive Publication Date: 2008-11-06
MERCK SHARP & DOHME CORP
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about compounds that can stop, modify, or control the action of certain proteins called tyrosine kinases. One specific compound is described in this patent, and its salts and forms are also described. This invention can be useful in developing new treatments for diseases that are influenced by these proteins.

Problems solved by technology

In fact, tumor growth has been shown to be susceptible to the antiangiogenic effects of VEGF receptor antagonists.
This vascular growth in the retina leads to visual degeneration culminating in blindness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tyrosine kinase inhibitors
  • Tyrosine kinase inhibitors
  • Tyrosine kinase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

examples

[0309]Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be illustrative of the invention and not limiting of the reasonable scope thereof.

2-Chloro-3-iodo-quinoline (1-2)

[0310]A suspension of 3-(2-chloro)-quinolineboronic acid (1-1, 5.05 g, 24.3 mmol, 1 equiv, prepared by the method of Marsais, F; Godard, A.; Queguiner, G. J Heterocyclic Chem. 1989, 26, 1589-1594) and N-iodosuccinimide (5.48 g, 24.4 mmol, 1.00 equiv) in acetonitrile (300 mL) was stirred at 23° C. in the dark for 20 h. The reaction mixture was concentrated to dryness, and the resulting yellow solid was partitioned between saturated aqueous sodium bicarbonate solution and dichloromethane. The organic layer was washed with water, then dried over magnesium sulfate and concentrated to give 2-chloro-3-iodo-quinoline as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 7.99 (br d, 1H, J=8.4 Hz), 7.75 (br t, 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Description

RELATED APPLICATIONS[0001]This application claims priority under 35 U.S.C. § 119(e) from U.S. Provisional Application 60 / 160,356 filed Oct. 19, 1999.BACKGROUND OF THE INVENTION[0002]The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.[0003]Tyrosine kinases are a class of enzymes that catalyze the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates. Tyrosine kinases are believed, by way of substrate phosphorylation, to play critical roles in signal transduction for a number of cell functions. Though the exact mechanism of signal transduction is still unclear, tyrosine kinases h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07D215/20A61K31/337A61K31/445A61K31/47A61K31/495A61K45/06A61P43/00C07D401/14C07D405/14C07D409/14C07D413/14C07D417/14
CPCA61K31/495A61K45/06C07D401/14C07D405/14C07D409/14C07D413/14C07D417/14A61K2300/00A61P43/00
Inventor FRALEY, MARK E.ARRINGTON, KENNETH L.BILODEAU, MARK T.HARTMAN, GEORGE D.HOFFMAN, WILLIAM F.KIM, YUNTAEHUNGATE, RANDALL W.
Owner MERCK SHARP & DOHME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com